NCT02055274View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Parkinson's Disease
Interventions
DRUG

LY03003

DRUG

Neupro

Trial Locations (5)

30134

West Georgia Sleep Disorders Center and Neurology Associates, Douglasville

32806

Compass Research LLC, Orlando

48025

Quest Research Institute, Bingham Farms

90806

Collaborative Neuroscience Network LLC, Long Beach

08053

PRA - CRI Lifetree, Marlton

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT02055274 - Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease | Biotech Hunter | Biotech Hunter